anticonvulsant

Trimethadione (3,5,5-Trimethyloxazolidine-2,4-dione) is a dione-type anticonvulsant with antiepileptic activity.

Cinromide (trans-3-Bromo-N-ethylcinnamamide) is used as a novel anticonvulsant agent.

Oxcarbazepine (GP 47680) is an Anti-epileptic Agent. The physiologic effect of oxcarbazepine is by means of Decreased Central Nervous System Disorganized Electrical Activity.

Clomethiazole (Distraneurin) is an orally active GABAA agonist and it is an anticonvulsant agent. It also has the potential for treating convulsive status epilepticus. Chlormethiazole inhibits cytochrome P450 isoforms: CYP2A6 and CYP2E1 in human liver microsomes.

Valproic acid sodium salt (Sodium Valproate) is the sodium salt form of valproic acid with anti-epileptic activity. Valproic acid sodium salt is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, Valproic acid sodium salt increases concentrations of gamma-aminobutyric acid (GABA) in the brain, probably due to inhibition of the enzymes responsible for the catabolism of GABA. This potentiates the synaptic actions of GABA. Valproic acid sodium salt may also affect potassium channels, thereby creating a direct membrane-stabilizing effect.

Ivabradine hydrochloride (S 16257-2) is a new If inhibitor (IC50: 2.9 μM). Ivabradine Hydrochloride is the hydrochloride salt form of ivabradine, an orally bioavailable, hyperpolarization-activated, cyclic nucleotide-gated (HCN) channel blocker, with negative chronotropic activity. Upon administration, ivabradine selectively binds to the intracellular portion of the HCN channel pore and blocks HCN channels in the pacemaker cells within the sinoatrial (SA) node. This inhibits the If (funny) pacemaker ion current, prevents the inward flow and intracellular accumulation of positively charged ions, reduces pacemaker activity and slows diastolic depolarization.

Cyclohexanecarboxylic acid is a flavouring ingredien

Divalproex Sodium (Valproate semisodium) binds to and inhibits gamma-aminobutyric acid (GABA) transaminase and its anticonvulsant activity may be exerted by increasing brain concentration of GABA and by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. It also is an HDAC inhibitor, Comprised of sodium valproate and valproic acid with anticonvulsant and antiepileptic activities. Divalproex may also work by suppressing repetitive neuronal firing through the inhibition of voltage-sensitive sodium channels.

Epoxylinalool (2-(2-Hydroxy-2-Propyl)-5-Methyl-5-Vinyltetrahydrofuran) is a naturally occurring monoterpene alcohol widely used in the production of perfumes and flavors.

(E)-3,4,5-Trimethoxycinnamic acid (O-Methylsinapic acid) is a natural compound derived from the roots and rhizomes of Notopterygium incisum.

ICA-27243 is less effective at activating KCNQ4 and KCNQ3 Q5. ICA-27243 is a potent and orally active KCNQ2 Q3 potassium channel opener (EC50: 0.38 μM). ICA-27243 also has antiepileptic and anticonvulsant effects.

Norfluoxetine Hydrochloride (Norfluoxetine HCl) is an active metabolite of fluoxetine. Fluoxetine is an antidepressant drug.

SB 271046 hydrochloride (SB 271046A) is selective, orally active 5-HT6 antagonist (pKi values are 9.02-8.92, 6.35, 6.55, 6.27 at 5-HT6, 5-HT1A, 5-HT1D and D3, and 6.05, 5.95, 5.76, 5.73, 5.62, 5.55, 5.41, 5.39, 5.27 and < 4.99 at 5-HT1B, 5-HT1F, α1B, 5-HT2C, 5-HT2A, D2, 5-HT2B, 5-HT7, 5-HT4 and 5-HT1E respectively) and is > 200-fold selective over 55 other receptors, enzymes and ion channels. It increases extracellular aspartate and glutamate in the frontal cortex and exhibits anticonvulsant activity (EC50: 0.16 μM).

Dizocilpine (MK-801) is a selective non-competitive NMDA receptor antagonist with a Kd of 37.2 nM that exhibits anticonvulsant effects. It acts by binding to a site within the NMDA-associated ion channel, blocking the flow of Ca²⁺, and is commonly used to establish schizophrenia models.

Blarcamesine (AVex-73) is a muscarinic M1 agonist potentially for the treatment of Alzheimer's disease.

Anticonvulsant agent 1 is a chemical compound with potent anticonvulsant properties.

Anticonvulsant agent 2 is a potent, orally active anticonvulsant demonstrating antiepileptic activity in a drug-resistant epilepsy model.

5-[(1S,2S)-2-[(Cyclopropylmethyl)amino]cyclopropyl]-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide hydrochloride is a cyclopropanoid enzyme compound that acts as a lysine-specific demethylase-1 inhibitor for schizophrenia, developmental disorders, and neurodegenerative diseases.

Anticonvulsant agent 9 (compound 4f) is an activator of the α1β2γ2GABA_A receptor, with an EC50 value of 1.24 μM. It inhibits the inactivation of Nav1.2 channels and exhibits significant anticonvulsant activity.

Anticonvulsant agent 8 (compound D4) is a chemical used in treating epilepsy by inhibiting GABAA currents. In mouse models, its ED50 values are 2.23 mg kg for the maximal electroshock (MES) test and 24.60 mg kg for the pentylenetetrazol (PTZ) test.

Anticonvulsant agent 7 (Compound 19) is an orally active, broad-spectrum anticonvulsant demonstrating excellent anticonvulsant activity in the MES (maximum electroshock) and 6 Hz seizure models.

Anticonvulsant agent 10 (Compound 6d) is an inhibitor targeting the Keap1-Nrf2 interaction, with a strong activity showing an ED50 of 0.04 mmol/kg. By inhibiting the Keap1-Nrf2 binding, it activates the Nrf2/ARE pathway, providing anticonvulsant and neuroprotective effects, making it useful for research in epilepsy and neuroprotection.

Anticonvulsant agent 3, a 2-amino derivative, exhibits anticonvulsant activity [1].

Compound 5c (Anticonvulsant agent 5) exhibits high affinity for GABAA receptors (GABAA receptor) and NaV1.3 receptors (NaV1.3 receptor). In the murine psychomotor seizure test, it demonstrated anticonvulsant activity with an ED50 of 107 mg kg. Additionally, Compound 5c shows neuroprotective effects against Kainic acid with an IC50 of 113 μM and possesses blood-brain barrier (BBB) permeability.